Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samia Mora

Showing results (101-110 of 260) with videos related to

Pageof 26
Sort By:
JACC. Advances|October 8, 2025
Development and Validation of Novel Residual Risk Scores for Patients With ASCVDOlga Mineeva, Chunying Li, Franco Giulianini, et al.
Circulation|April 20, 2005
Interaction of body mass index and framingham risk score in predicting incident coronary disease in familiesSamia Mora, Lisa R Yanek, Taryn F Moy, et al.
Diabetes Care|January 27, 2011
Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. womenTariq Ahmad, I-Min Lee, Guillaume Paré, et al.
Circulation|July 20, 2018
Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease IncidenceAaron W Aday, Patrick R Lawler, Nancy R Cook, et al.
Journal of the Endocrine Society|June 6, 2017
Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in WomenPaulo H N Harada, Julie E Buring, Nancy R Cook, et al.
Journal of the American College of Cardiology|April 21, 2012
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)Samia Mora, Robert J Glynn, S Matthijs Boekholdt, et al.
Journal of the American College of Cardiology|December 3, 2021
Exercise-Induced Ventricular Ectopy and Cardiovascular Mortality in Asymptomatic IndividualsMarwan M Refaat, Charbel Gharios, M Vinayaga Moorthy, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|May 8, 2023
Social Determinants of Health and Mortality After Premature and Non-premature Acute Coronary SyndromeSagar B Dugani, Mohammad Zubaid, Wafa Rashed, et al.
European Heart Journal|March 30, 2013
Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imagingDeepak Thomas, Mouaz Al-Mallah, Usha Govindarajulu, et al.
Circulation|October 22, 2014
Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"Amit V Khera, Brendan M Everett, Michael P Caulfield, et al.
Pageof 26

Showing results (101-110 of 260) with videos related to

Sort By:
Pageof 26
JACC. Advances|October 8, 2025
Development and Validation of Novel Residual Risk Scores for Patients With ASCVDOlga Mineeva, Chunying Li, Franco Giulianini, et al.
Circulation|April 20, 2005
Interaction of body mass index and framingham risk score in predicting incident coronary disease in familiesSamia Mora, Lisa R Yanek, Taryn F Moy, et al.
Diabetes Care|January 27, 2011
Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. womenTariq Ahmad, I-Min Lee, Guillaume Paré, et al.
Circulation|July 20, 2018
Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease IncidenceAaron W Aday, Patrick R Lawler, Nancy R Cook, et al.
Journal of the Endocrine Society|June 6, 2017
Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in WomenPaulo H N Harada, Julie E Buring, Nancy R Cook, et al.
Journal of the American College of Cardiology|April 21, 2012
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)Samia Mora, Robert J Glynn, S Matthijs Boekholdt, et al.
Journal of the American College of Cardiology|December 3, 2021
Exercise-Induced Ventricular Ectopy and Cardiovascular Mortality in Asymptomatic IndividualsMarwan M Refaat, Charbel Gharios, M Vinayaga Moorthy, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|May 8, 2023
Social Determinants of Health and Mortality After Premature and Non-premature Acute Coronary SyndromeSagar B Dugani, Mohammad Zubaid, Wafa Rashed, et al.
European Heart Journal|March 30, 2013
Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imagingDeepak Thomas, Mouaz Al-Mallah, Usha Govindarajulu, et al.
Circulation|October 22, 2014
Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"Amit V Khera, Brendan M Everett, Michael P Caulfield, et al.
Pageof 26